Nitrergic Function Is Lost but Endothelial Function Is Preserved in the Corpus Cavernosum and Penile Resistance Arteries of Men after Radical Prostatectomy

Juan I. Martínez-Salamanca, MD, PhD,* José M. La Fuente, MD, PhD,[†] Argentina Fernández, LT,[‡] Eduardo Martínez-Salamanca, LT,[‡] Augusto J. Pepe-Cardoso, MD,[§] Joaquín Carballido, MD, PhD,* and Javier Angulo, PhD[‡]

*Servicio de Urología, Hospital Universitario Puerta de Hierro, Madrid, Spain; †Serviço de Urologia, Hospital Santo Antonio, Porto, Portugal; †Unidad de Investigación Traslacional en Cardiología, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Hospital Universitario Ramón y Cajal, Madrid, Spain; [§]Serviço de Urologia, Hospital Amadora-Sintra, Lisboa, Portugal

DOI: 10.1111/jsm.12801

ABSTRACT-

Introduction. Radical prostatectomy (RP) frequently results in erectile dysfunction (ED). It has been hypothesized that alterations of cavernosal tissue subsequent to RP contribute to ED but functional evaluation of the impact of RP on human erectile structures is lacking.

Aim. This study aims to evaluate endothelial function of human corpus cavernosum (HCC) and human penile resistance arteries (HPRA) and neurogenic responses of HCC from patients with ED secondary to RP (ED-RP).

Methods. HCC strips and HPRA were obtained from organ donors without history of ED (No-ED) and patients with ED who were segregated depending on ED etiology: ED-RP or vasculogenic (ED-VASC). Functional evaluation of HCC and HPRA was performed in organ chambers and wire myographs, respectively. Histological evaluation of cavernosal tissue consisted of trichrome staining for fibrosis quantification and TUNEL assay for determination of apoptosis.

Main Outcome Measures. Endothelium-dependent and endothelium-independent relaxation, electrical field stimulation (EFS)-induced neurogenic contraction and relaxation, and cavernosal fibrosis and apoptosis.

Results. Endothelium-dependent relaxations were significantly impaired in HCC and HPRA from ED-VASC patients while these responses in ED-PR patients were not different to No-ED. Similarly, sildenafil-induced relaxations were reduced in HCC and HPRA from ED-VASC but were preserved in ED-RP. Adrenergic contractions induced by EFS in HCC were potentiated in both ED-RP and ED-VASC. EFS-induced nitrergic relaxation was significantly reduced in HCC from ED-VASC but was almost abolished in ED-RP. Fibrous tissue content and cavernosal apoptosis in HCC from ED-RP were not significantly different from No-ED.

Conclusions. Endothelial function and cavernosal sensitivity to phosphodiesterase type 5 inhibitors are preserved in erectile tissue from ED-RP while a marked imbalance in neurogenic modulation of cavernosal tone favoring adrenergic contractile responses over nitrergic relaxation is manifested. Fibrotic and apoptotic processes in cavernosal tissue are not specifically associated to ED-RP. These evidences could help to retarget therapeutic strategies in the management of ED after RP. Martínez-Salamanca JI, La Fuente JM, Fernández A, Martínez-Salamanca E, Pepe-Cardoso AJ, Carballido J, and Angulo J. Nitrergic function is lost but endothelial function is preserved in the corpus cavernosum and penile resistance arteries of men after radical prostatectomy. J Sex Med 2015;12:590–599.

Key Words. Erectile Dysfunction; Radical Prostatectomy; Human Corpus Cavernosum; Endothelium-Dependent Relaxation; Nitrergic Relaxation; Penile Rehabilitation

Introduction

 ${f R}$ adical prostatectomy (RP) remains the reference treatment for organ-confined prostate cancer in patients with a life expectancy of 10 years or more [1], but despite the advent of nerve sparing techniques, it often causes sustained erectile dysfunction (ED) [2,3]. Postprostatectomy erectile dysfunction (ED-RP) typically results from injury to the cavernous nerves that course along the posterolateral aspects of the prostate and provide most of the autonomic input to the erectile tissue. It is estimated that 10% of all men experiencing ED suffer the condition as a result of surgical procedure, typically, radical pelvic surgery. Major discrepancy exists in the literature regarding postoperative potency rates with spontaneous erectile function occurring in 20-80% of patients [4-8].

Patients with ED-RP are poor responders to phosphodiesterase type 5 inhibitors (PDE5) [9], which represent the first-line therapy for the treatment of ED. Nevertheless, early and continuous administration of these compounds have been proposed to prevent the progression of fibrosis [10,11] and produce a positive effect on erectile function in ED-RP, but the recovery of erectile function is obtained in a limited percentage of patients [12–15].

It is thought that RP causes structural and functional alterations in erectile tissue through inducing hypoxia/fibrosis, vascular insufficiency, and/or neurological degeneration. However, this is based on results obtained in rat models of cavernous nerve injury [16–18] and a very limited number of histological/immunohistological studies in human cavernosal tissue [19,20]. Thus, functional evaluation of human erectile tissue after RP in comparison with other types of ED is definitely lacking.

The aim of this work was to evaluate the impact of RP on endothelial and neurogenic responses of human corpus cavernosum (HCC) and human penile resistance arteries. The functional characteristics of erectile tissue from patients with ED-RP were compared with those from patients with vascular ED, and structural alterations of cavernosal tissue were also evaluated.

Materials and Methods

Human Tissues

HCC specimens were obtained from organ donors without history of ED (No-ED) at the time of organ collection for transplantation and from men with ED who gave written informed consent at the time of penile prosthesis implantation. ED patients were segregated depending on ED etiology: secondary to RP (ED-RP) or due to vascular causes (ED-VASC). Organ donors relatives signed consent for tissue collection for research purposes following Portuguese rules and the protocol approved by the Hospital Santo Antonio, Porto, Portugal. Protocols and consent forms signed by ED patients were approved by the Ethic Committees at the hospitals where the tissues were collected in Portugal and Spain (081/10(059-DEFI/077-CES) and Acta 256/28-06-10). Tissues were maintained at 4-6°C in M-400 solution (composition per 100 mL: mannitol, 4.19 g; KH₂PO₄, 0.205 g; K₂HPO₄·3H₂O, 0.97 g; KCl, 0.112 g; NaHCO₂, 0.084 g; pH 7.4) until their use, which ranged between 16 and 24 hours from extraction [21,22].

Functional Evaluation of Corpus Cavernosum

Strips of corpus cavernosum tissue $(3 \times 3 \times 7 \text{ mm})$ were immersed in 8 mL organ chambers containing Krebs-Henseleit solution (KHS) of the following composition (mM): NaCl 119, KCl 4.6, CaCl₂ 1.5, MgCl₂ 1.2, NaHCO₃ 24.9, glucose 11, KH₂PO₂ 1.2, ethylenediamine tetraacetic acid (EDTA) 0.027, maintained at 37°C and aerated with 95% O₂/5% CO₂, pH 7.4, for isometric tension recording as previously described [21,22]. Each tissue strip was incrementally stretched to optimal isometric tension, as determined by maximal contractile response to 1 µM phenylephrine (PE). The preparations were then exposed to 120 mM K⁺, and the contractile response was measured. Relaxation responses were evaluated in strips contracted with PE (1–3 μ M; 80% of K⁺-induced contraction) by cumulative additions of compounds to the chambers. Electrical field stimulation (EFS) was applied to HCC strips by means of two platinum electrodes placed at both sides of the tissue and connected to a current stimulator (Cibertec, Madrid, Spain). Parameters of EFS were: 75 mA, 0.5 ms for 20 seconds. Neurogenic contractile responses to EFS (0.5-48 Hz) were obtained in untreated, noncontracted strips. For evaluating nitrergic relaxations, the tissues were pretreated with atropine (0.1 μ M) and guanethidine (30 μ M), and EFS was applied at 0.5–16 Hz to HCC strips precontracted with PE (1–3 μ M).

Vascular Reactivity of Human Penile Resistance Arteries

Penile small arteries, helicine arteries (lumen diameter $150-400 \mu m$), were dissected by carefully

removing the adhering trabecular tissue, and arterial ring segments (2 mm long) were subsequently mounted on wire myographs (J.P. Trading, Aarhus, Denmark) for isometric tension recordings as previously described [21,22]. The vessels were allowed to equilibrate for 30 minutes in KHS at 37°C continuously bubbled with 95% O₂/5% CO_2 mixture to maintain a pH of 7.4. The arteries were then set to 90% of determined internal circumference under a transmural pressure of 100 mm Hg (L_{100}), at which the force development was close to maximal. The preparations were then exposed to 120 mM K⁺, and the contractile response was measured. The arteries were contracted with 1-3 µM norepinephrine (80% of K⁺-induced contraction approximately) and relaxation responses were evaluated by cumulative additions of compounds to the chambers.

Determination of Cavernosal Apoptosis and Fibrosis

Apoptosis was determined by terminal 2 deoxyuridine-5 -triphosphate nick-end-labeling (TUNEL) assay in deparaffined tissue sections (6 µm) of corpus cavernosum. A uorescencebased commercial kit was used following manufacturer s specifications (Promega Biotech Ibérica, Alcobendas, Spain). Percentage of apoptosis was calculated by counting apoptotic cell nuclei (TUNEL-positive cells) relative to total number of cell nuclei in six high-magnification visual fields (×400) for each sample. For determination of cavernosal fibrosis, deparaffined tissue sections (6 µm) were stained with Masson s trichrome and the percentage of the area stained in blue (fibrotic tissue) with respect to total area of highmagnification visual fields ($\times 200$) (five per patient) was calculated by using morphometric software (Image J, National Institutes of Health, Bethesda,

Table 1	Main	characteristics	of t	he i	oatients
---------	------	-----------------	------	------	----------

MD, USA). Photograph capture and quantification were performed by two different investigators who were unaware of the classification of the analyzed tissue.

Data Analysis

Relaxation responses are expressed as the percentage of total relaxation (loss in tone) induced by the addition of 0.1 mM papaverine to the chambers at the end of the experiment. pD_2 is defined as the -log molar concentration required to obtain 50% of maximal relaxation. It was graphically calculated for each individual curve. EFS-induced contractions are expressed as the percentage of the contraction elicited by 120 mM K⁺ in each tissue. All data are expressed as mean ± standard error. Complete concentrationresponse or frequency-response curves were obtained and compared by a two-factor analysis of variance (ANOVA) statistical test using StatView software for Apple computers (SAS, Cary, NC, USA) [23]. All other data were compared by onefactor ANOVA, followed by a Student-Newmann-Keuls posttest (GraphPad InStat, San Diego, CA, USA).

Results

Endothelium-Dependent Relaxation Is Preserved in Both HCC and Penile Resistance Arteries (HPRA) from ED-RP

Main characteristics of patients from whom the tissues were collected are displayed in Table 1. As expected, an elevated presence of cardiovascular risk factors and cardiovascular disease was found in ED-VASC while only the frequency of hypertension was significantly elevated in ED-RP with respect to No-ED subjects.

	No ED	ED-VASC	ED-RP	
<u>n</u>	20	30	29	
Age, years	55.0 ± 2.9	58.3 ± 1.2	60.9 ± 1.5	
(range)	(23–76)	(41–70)	(44–72)	
Diabetes (%)	0 (0)	15 (50.0)***	1 (3.4)***	
Hypertension (%)	2 (10)	17 (56.7)***	10 (34.5)*	
Dyslipidemia (%)	0 (0)	9 (30.0)**	5 (17.2)	
Obesity (%)	0 (0)	3 (10.0)	0 (0)	
Cardiovascular disease (%)	0 (0)	5 (16.7)	0 (0)	
IIEF-5 score (range)	_ ()	7.8 ± 1.5 (5–9)	8.0 ± 1.5 (5–10)	
Time from prostatectomy, months	—		34.6 ± 5.0	

*P < 0.05, **P < 0.01, ***P < 0.001 vs. No-ED and †††P < 0.001 vs. ED-VASC by Fisher's exact test.

No-ED = organ donors without history of erectile dysfunction (ED); ED-VASC = patients with ED of vascular aetiology; ED-RP = patients with ED after radical prostatectomy; IIEF-5 = International Index of Erectile Function—erectile function domain.

		HCC		HPRA	
		pD ₂	E _{max} (%)	pD2	E _{max} (%)
No-ED		6.39 ± 0.24 n = 6	76.3 ± 5.9	7.31 ± 0.29 n = 6	88.2 ± 3.5
ED-VASC		5.41 ± 0.21** n = 10	$53.4\pm5.1^{\star}$	5.57 ± 0.30*** n = 9	57.6 ± 5.7***
ED-RP ED-RP subgroups		6.49 ± 0.13 ^{††} n = 10	$73.5\pm2.5^{\dagger}$	7.13 ± 0.18 ⁺⁺⁺ n = 11	$88.0\pm2.0^{\dagger\dagger\dagger}$
	Rehab	6.47 ± 0.03 n = 4	76.2 ± 2.9	6.96 ± 0.52 n = 4	89.9 ± 3.3
	No Rehab	6.50 ± 0.16 n = 6	71.1 ± 3.2	7.18 ± 0.17 n = 7	87.1 ± 3.0
	NSRP	6.42 ± 0.16 n = 4	75.2 ± 2.9	6.99 ± 0.33 n = 4	90.8 ± 3.1
	Non-NSRP	6.54 ± 0.20 n = 6	72.1 ± 3.4	7.19 ± 0.22 n = 7	87.6 ± 2.6

Table 2 Parameters of endothelium-dependent relaxation induced by acetylcholine in human corpus cavernosum (HCC) and penile resistance arteries (HPRA) from different patient groups and subgroups

*P<0.05, **P<0.01, ***P<0.001 vs. No-ED, and †P<0.05, ††P<0.01, ††+P<0.001 vs. ED-VASC by one-factor ANOVA followed by Student–Newmann–Keuls test. No significant differences between ED-RP subgroups were obtained.

pD₂ is defined as the –log M of the concentration of acetylcholine (ACh) to obtain 50% of total relaxation. E_{max} is the maximum percentage of relaxation achieved with any ACh concentration. Data are expressed as mean ± SEM. NSRP indicates nerve-sparing radical prostatectomy. Rehab indicates penile rehabilitation with PDE5 inhibitors. n indicates the number of patients included for determinations.

No-ED = organ donors without history of erectile dysfunction (ED); ED-VASC = patients with ED of vascular aetiology; ED-RP = patients with ED after radical prostatectomy.

Endothelium-dependent relaxations induced by acetylcholine (ACh, 1 nM to 10 μ M) in HCC were significantly reduced in ED-VASC when compared with those obtained in HCC from No-ED. In contrast, endothelium-dependent relaxations in HCC from ED-RP were not impaired (Table 2) (Figure 1A). Similar results were obtained when endothelium-dependent vasodilation was evaluated in HPRA, as AChinduced vasodilations were significantly impaired in HPRA from ED-VASC with respect to No-ED but those in ED-RP remained unaltered (Table 2) (Figure 1B).

Preservation of endothelial function was not due to the application of penile rehabilitation procedures as a small number of patients from our sample underwent this clinical approach after RP. In fact, responses to ACh in penile tissues from this specific population were not different from that obtained from ED-RP patients who did not




Figure 1 Endothelium-dependent relaxations induced by acetylcholine (ACh; 1 nM to 10 μ M) in human corpus cavernosum strips (HCC) (A) and human penile resistance arteries (HPRA) (B) from organ donors without history of ED (No ED), patients with ED not related to radical prostatectomy (ED-VASC) or patients with ED secondary to radical prostatectomy (ED-RP) previously contracted with phenylephrine (1–3 μ M) (1.87 ± 0.49, 1.70 ± 0.23 and 1.69 ± 0.19 g, respectively; *P* = 0.9102) and norepinephrine (1–3 μ M) (7.55 ± 0.50, 7.28 ± 0.98 and 7.35 ± 0.82 mN, respectively; *P* = 0.7613), respectively. Data are expressed as mean ± SEM of the percentage of maximal relaxation induced by papaverine (0.1 mM). n indicates the number of patients. *** indicates *P* < 0.001 vs. No-ED or ED-RP by a two-factors ANOVA.




Figure 2 Relaxations induced by the PDE5 inhibitor, sildenafil (1 nM to 10 μ M) in human corpus cavernosum strips (HCC) (A) and human penile resistance arteries (HPRA) (B) from organ donors without history of ED (No-ED), patients with ED not related to radical prostatectomy (ED-VASC) or patients with ED secondary to radical prostatectomy (ED-RP) previously contracted with phenylephrine (1–3 μ M) (1.99 ± 0.36, 1.84 ± 0.27 and 1.95 ± 0.32 g, respectively; *P* = 0.9363) and norepinephrine (1–3 μ M) (6.73 ± 0.68, 7.65 ± 1.22 and 7.58 ± 0.87 mN, respectively; *P* = 0.5991), respectively. Data are expressed as mean ± SEM of the percentage of maximal relaxation induced by papaverine (0.1 mM). n indicates the number of patients. *** indicates *P* < 0.001 vs. No-ED or ED-RP by a two-factors ANOVA.

undergo penile rehabilitation with PDE5 inhibitors (Table 2). In the same way, adoption of nerve sparing techniques for RP did not modify the endothelium-dependent relaxations (Table 2).

Similarly, relaxations to the PDE5 inhibitor, sildenafil, were significantly impaired in both HCC and HPRA from ED-VASC, whereas the relaxant and vasodilatory capacities of the PDE5 inhibitor were preserved in HCC and HPRA from ED-RP (Figure 2). HCC from ED patients, either from ED-VASC or ED-RP, displayed unaltered endothelium-independent relaxations to the NO-donor, sodium nitroprusside (SNP; 1 nM to 10 μ M) when compared with HCC from No-ED (pD₂ 7.39 ± 0.07, 7.31 ± 0.06 and 7.34 ± 0.09 for No-ED, ED-VASC, and ED-RP, respectively; n.s.).

ED Secondary to RP Is Associated to an Impairment of Nitrergic Relaxation and Enhanced Neurogenic Contraction of HCC

In HCC strips contracted with PE and treated with guanethidine (30 μ M) to inhibit adrenergic neurotransmission, and atropine (0.1 μ M) to block muscarinic receptors, EFS application (0.5–16 Hz) resulted in frequency-dependent relaxations. Relaxations were nitrergic in nature since were abolished by inhibiting NO synthesis with L-NAME (100 μ M) (Figure 3A). Nitrergic relaxations were significantly reduced in HCC from ED-VASC but were more profoundly impaired in HCC from ED-RP (Figure 3C and D). In contrast, neurogenic contractions of HCC in response to EFS (0.5–48 Hz) were not simply preserved but

were significantly enhanced in ED-RP to the same extent as those in ED-VASC (Figure 3E). Contractile responses induced by EFS were mediated by adrenergic system as they were prevented by α -adrenergic receptor blockade with phentolamine $(1 \mu M)$ (Figure 3B). The potentiated response was not related to an alteration of contractile responses to adrenergic receptor stimulation of the ED-RP tissues as contractions induced by PE for relaxation experiments were not significantly different among the three groups of patients (2.05 ± 0.24) , 1.84 ± 0.17 , and 1.85 ± 0.16 g for No ED, ED-VASC, and ED-RP, respectively; n.s.). ED-VASC and ED-RP were not only associated to enhanced contractility of HCC to EFS but were also related to increased sensitivity to neurogenic stimulation because the frequency required for obtaining 50% of maximal response (EF₅₀) in HCC from these patients was significantly lower $(27.0 \pm 0.9, 18.5 \pm 2.0 \text{ and } 19.9 \pm 0.9 \text{ Hz}$ for No ED, ED-VASC and ED-RP, respectively; P < 0.001 for both groups of ED patients vs. No-ED).

Nitrergic relaxations in HCC from ED-RP patients who underwent nerve-sparing surgery for RP (NSRP) were not significantly different from those ED-RP not specifically submitted to NSRP (non-NSRP). Maximal relaxation to EFS was $16.1 \pm 5.5\%$ for non-NSRP (n = 9) and $24.5 \pm 6.1\%$ for NSRP (n = 5; n.s.). Similarly, the enhancement of neurogenic contractions was also present in ED-RP patients undergoing NSRP. In fact, EFS-induced contractions tended to increase in this specific population (E_{max} 15.9 ± 4.8% vs.




Figure 3 Panel A shows a representative tracing of neurogenic relaxation induced by electrical field stimulation (EFS) in a human corpus cavernosum (HCC) strip contracted with phenylephrine (1 μ M) and treated with guanethidine (30 μ M) and atropine (0.1 μ M) that was prevented by inhibition of NO synthesis with N^G-nitro-L-arginine-methyl-ester (L-NAME, 100 μ M). Panel B shows a representative tracing of neurogenic contraction induced by EFS in an untreated HCC strip that was prevented by α -adrenergic receptor blockade with phentolamine (1 μ M). HCC strips in panels A and B were obtained from a patient with ED not related to radical prostatectomy (ED-VASC) although this result is applicable to any other patient group. Panel C shows representative nitrergic relaxations in HCC strips contracted with PE (1 μ M) from an organ donor without history of ED (No-ED), an ED-VASC patient and a patient with ED secondary to radical prostatectomy (ED-RP). Lower panels show quantification of nitrergic relaxations in HCC strips contracted with PE (1–3 μ M) (2.33 ± 0.43, 2.16 ± 0.47 and 1.90 ± 0.31 g, respectively; *P* = 0.7399) (D) and adrenergic contractions in untreated HCC strips (E). Data are expressed as mean ± SEM of the percentage of maximal relaxation induced by papaverine (0.1 mM) (D) and as mean ± SEM of the percentage of maximal relaxation induced by papaverine (0.1 mM) (D) and as mean ± SEM of the percentage of contraction elicited by 120 mM K⁺ (E). n indicates the number of patients. *** indicates *P* < 0.001 vs. No-ED, ††† *P* < 0.001 vs. ED-VASC by a two-factor ANOVA.

 $47.1 \pm 24.6\%$ for non-NSRP [n = 11] and NSRP [n = 5], respectively; n.s.).

The time passed from RP did not seem to be critical for the manifestation of altered neurogenic imbalance in HCC from ED-RP. This is based on the lack of significant correlation between time after RP and maximal nitrergic relaxation $(r^2 = 0.001; \text{ n.s.})$ or maximal adrenergic contraction $(r^2 = 0.093; \text{ n.s.})$.

Cavernosal Apoptosis and Fibrosis Are not Specifically Linked to ED Secondary to RP

Fibrotic tissue content in HCC was slightly but significantly elevated in ED-VASC. This signifi-




Figure 4 Detection of fibrosis by trichrome staining (A) and apoptosis by TUNEL (B) in human corpus cavernosum (HCC) from organ donors without history of ED (No-ED), patients with ED not related to radical prostatectomy (ED-VASC) or patients with ED secondary to radical prostatectomy (ED-RP). Data are expressed as mean ± SEM of the percentage of the area occupied by fibrotic tissue in each field (\times 200) (A) and as mean \pm SEM of the percentage of apoptotic nuclei (B). n indicates the number of patients. * indicates P < 0.05 vs. No ED by a one-factor ANOVA followed by Student-Newmann-Keuls test. Upper panels show representative images. Arrows indicate apoptotic nuclei.

cant increase in fibrosis was not manifested in HCC from ED-RP, although fibrous tissue content in HCC from these patients was not significantly different from that determined in ED-VASC (Figure 4A). There were no significant differences among the groups of subjects with respect to the presence of apoptosis in cavernosal tissue (Figure 4B).

Discussion

It has been proposed that neurapraxia/damage of cavernous nerves during radical pelvis surgery causes erectile incapacity, cavernosal in ammation, and hypoxia leading to defective nitric oxide/ cyclic guanosine monophosphate (NO/cGMP) pathway and oxidative stress that harm endothelium and smooth muscle resulting in cavernosal fibrosis. Then, when this process is completed, a potential nerve restoration could find an unresponsive erectile tissue that would impede erectile function recovery and would explain the high rate of permanent ED after RP even when nerve sparing techniques are applied [9,24]. This view of ED-RP pathophysiology represents the rationale for penile rehabilitation that has been extensively evaluated and widely applied to patients undergoing RP, mainly by chronic administration of PDE5 inhibitors. However, although based on very reasonable concepts, the research evidence supporting this hypothesis is limited to animal models that manifest substantial morphological alterations of

J Sex Med 2015;12:590-599

penile tissue architecture, including increased apoptosis, smooth muscle/endothelium loss and fibrosis [16–18,25,26], and to scarce histological evaluation of human tissue after RP [19,20].

Reduced number of elastic fibers, decreased smooth muscle, and increased collagen content has been found in cavernosal biopsies from men undergoing RP [19]. However, these observations were not compared with other types of ED. In fact, in a general sample, the reduction in elastic fibers, smooth muscle, and endothelium content was more notable in ED patients with arterial disease, elevated age, diabetes and smoking habit [27]. A recent study showed significantly increased fibrosis and apoptosis in corpus cavernosum from prostatectomized patients with severe ED but these alterations were not significantly different from those in diabetic patients and even were lower in magnitude [20]. In addition, the status of prostatectomy population with respect to the presence of vascular risk factors was not reported.

To our knowledge, we provide the first functional evaluation of human erectile tissue obtained from patients with ED secondary to RP in comparison with healthy specimens and with those from patients with vasculogenic ED. Our results do not support a generalized degeneration of cavernosal tissue after RP as endothelial and smooth muscle relaxations are preserved in penile tissues. Accordingly, the relaxant capacity of the PDE5 inhibitor, sildenafil, is conserved intact in HCC and HPRA from ED-RP suggesting that the failure to PDE5 inhibition therapy does not relate to defective activity or tissue inability to relax. In fact, none of the non-neurogenic relaxant responses mediated by NO/cGMP pathway, namely ACh, sildenafil, and SNP, is altered in erectile tissues from ED-RP. In contrast, ED-VASC is associated with impaired endothelial relaxation and significantly reduced efficacy of sildenafil to relax HCC and to vasodilate HPRA, as previously reported [21].

The outstanding feature that specifically characterizes functional alterations induced by RP in human cavernosal tissue is a profound impairment of nitrergic relaxation. HCC from ED-RP displays nitrergic relaxations that are not only reduced with respect to healthy tissue but also are decreased with respect to ED-VASC, who manifest a milder reduction. Severe impairment of nitrergic responses is not related to a generalized deficit in neurogenic responses as adrenergic contractions induced by EFS in HCC from ED-RP are not reduced. Furthermore, these contractions are enhanced with respect to No-ED to the same extent as that observed in HCC from ED-VASC. The loss of nitrergic function could be responsible for this enhancement of neurogenic contractions in cavernosal tissues from ED-RP as NO/cGMP pathway modulates EFS-induced noradrenergic contractions in HCC [28]. Thus, neurogenic control of cavernosal tone in ED-RP is imbalanced favoring contractile responses over relaxant input. Studies using rat models of cavernous nerve injury (CNI) have consistently reported nitrergic degeneration in cavernosal tissue determined as a loss in nNOS positive nerve fibers [29,30]. In contrast, functional evaluation of rat corpus cavernosum after CNI demonstrated blunted nitrergic relaxations despite good regeneration of nitrergic nerves [31]. Although altered NO-mediated cavernosal smooth muscle relaxation was proposed for explaining this observation, it could be related to aberrant synapse formation in neuroregeneration after CNI [32]. In fact, in our human tissue model, none of the non-neurogenic relaxant responses mediated by NO/cGMP pathway are altered in erectile tissues from ED-RP.

On the other hand, the here reported enhancement of neurogenic contractions has no clear antecedent as the in uence of CNI on sympathetic nerves has not been previously addressed. However, the specific contribution of this alteration to ED after CNI deserves evaluation in the future since erectile function under these conditions could potentially benefit from adrenergic modulation.

Morphological evaluation of cavernosal specimens yielded results consistent with functional preservation of endothelial and smooth muscle responses, as fibrosis is not significantly increased in HCC from ED-RP, whereas tissues from ED-VASC display a significant elevation of fibrotic content. Furthermore, no evidence of increased apoptosis is detected in human cavernosal tissue from either ED-RP or ED-VASC. We did not find the significant fibrotic alterations previously described in cavernosal tissue from ED patients undergoing RP [19,20]. Although this could be due to differences in study population (no information on the presence or the absence of vascular risk factors was provided in those studies), our observations are supported by functional evidence. Furthermore, this concept would be consistent with the high efficacy of intracavernosal injections in postprostatectomy ED patients [33]. Based on our results, morphological aspect of human cavernosal tissue after RP substantially differs from that in rat cavernosal tissue in models of CNI, suggesting that differences between human disease and animal models could exist.

The present results do not support the widely accepted concept that rehabilitation with PDE5 inhibitors should be required for preservation of cavernosal endothelium and smooth muscle and would rather support critical points of view [34] as endothelial and smooth muscle relaxant capacity are preserved in ED-RP even in the absence of penile rehabilitation. This could explain the limited clinical improvement of erectile function obtained with PDE5 inhibitor administration right after surgery [13-15] despite the demonstrated clear beneficial impact on erectile function and cavernosal morphology in animal models of CNI when PDE5 inhibitors were continuously administered [29,30,35]. However, a potential benefit, related or not to endothelial function, driven by continuous PDE5 inhibitor administration cannot be discarded as some studies have yielded positive results with this approach [12]. In this sense, some preclinical studies suggest that PDE5 inhibition may increase blood ow to ganglia of nitrergic neurons preserving nitrergic function and facilitating nitrergic regeneration [36,37], although the positive effects of PDE5 inhibitors could be potentially contributed by the ability of these drugs to promote neurogenesis [38,39].

Despite the value of experimentation with human tissues, these studies bear some unavoidable limitations. In this sense, we lack information on the function of cavernosal tissue from patients undergoing RP but recovering erectile function. Collection of cavernosal tissue valid for functional assays from these patients is not possible as they do not require prosthesis implantation. In the same sense, it is not possible to afford longitudinal studies to explore the time-frame of functional alterations. On the other hand, the morphological analysis of nitrergic fibers in tissues from the different groups of subjects including those who were able to recover erectile function deserves future research efforts to complete the present functional findings.

Conclusions

An imbalance of neurogenic control of cavernosal tone favoring contractile responses over nitrergic relaxations is the main functional alteration of the erectile tissue from ED-RP, while endotheliumand smooth muscle-mediated relaxations are preserved. These results obtained after the first functional evaluation of human ED-RP tissues in comparison with both No ED and ED-VASC suggest that strategies directed to reverse neurogenic imbalance by recovering/preserving nitrergic responses and avoiding adrenergic enhancement could be of relevance in the management of ED after RP rather than those targeted to preserve endothelial and smooth muscle function.

Corresponding Author: Javier Angulo, PhD, Unidad de Investigación Traslacional en Cardiología, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Hospital Universitario Ramón y Cajal, Ctra. de Colmenar Viejo km 9.100, ES28034-Madrid, Spain. Tel: (34) 91-3368481; Fax: (34) 91-3368481; E-mail: javier.angulo@hrc.es; jangulo@ibercom.com

Con ict of Interest: The author(s) report no con icts of interest.

Statement of Authorship

Category 1

- (a) Conception and Design Juan I. Martínez-Salamanca; Javier Angulo
- (b) Acquisition of Data Juan I. Martínez-Salamanca; José M. La Fuente; Argentina Fernández; Eduardo Martínez-Salamanca; Augusto J. Pepe-Cardoso
- (c) Analysis and Interpretation of Data Juan I. Martínez-Salamanca; José M. La Fuente; Argentina Fernández; Eduardo Martínez-Salamanca; Augusto J. Pepe-Cardoso; Joaquín Carballido; Javier Angulo

Category 2

- (a) Drafting the Article Javier Angulo
- (b) Revising It for Intellectual Content

Juan I. Martínez-Salamanca; José M. La Fuente; Argentina Fernández; Eduardo Martínez-Salamanca; Augusto J. Pepe-Cardoso; Joaquín Carballido; Javier Angulo

Category 3

- (a) Final Approval of the Completed Article
 - Juan I. Martínez-Salamanca; José M. La Fuente; Argentina Fernández; Eduardo Martínez-Salamanca; Augusto J. Pepe-Cardoso; Joaquín Carballido; Javier Angulo

References

- 1 Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N. EAU Guidelines on prostate cancer. Part 1: Screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 2014;65:467–79.
- 2 Salonia A, Burnett AL, Graefen M, Hatzimouratidis K, Montorsi F, Mulhall JP, Stief C. Prevention and management of postprostatectomy sexual dysfunctions part 2: Recovery and preservation of erectile function, sexual desire, and orgasmic function. Eur Urol 2012;62:273–86.
- 3 Ficarra V, Novara G, Ahlering TE, Costello A, Eastham JA, Graefen M, Guazzoni G, Menon M, Mottrie A, Patel VR, Van der Poel H, Rosen RC, Tewari AK, Wilson TG, Zattoni F, Montorsi F. Systematic review and meta-analysis of studies reporting potency rates after robot-assisted radical prostatectomy. Eur Urol 2012;62:418–30.
- 4 Catalona WJ, Carvalhal GF, Mager DE, Smith DS. Potency, continence and complication rates in 1,870 consecutive radical retropubic prostatectomies. J Urol 1999;162:433–8.
- 5 Rabbani F, Stapleton AM, Kattan MW, Wheeler TM, Scardino PT. Factors predicting recovery of erections after radical prostatectomy. J Urol 2000;164:1929–34.
- 6 Tal R, Alphs HH, Krebs P, Nelson CJ, Mulhall JP. Erectile function recovery rate after radical prostatectomy: A metaanalysis. J Sex Med 2009;6:2538–46.
- 7 Nelson CJ, Scardino PT, Eastham JA, Mulhall JP. Back to baseline: Erectile function recovery after radical prostatectomy from the patients perspective. J Sex Med 2013;10:1636–43.
- 8 Schiavina R, Borghesi M, Dababneh H, Pultrone CV, Chessa F, Concetti S, Gentile G, Vagnoni V, Romagnoli D, Della Mora L, Rizzi S, Martorana G, Brunocilla E. Survival, continence and potency (SCP) recovery after radical retropubic prostatectomy: A long-term combined evaluation of surgical outcomes. Eur J Surg Oncol 2014;doi: 10.1016/j.ejso.2014.06.015.
- 9 Hatzimouratidis K, Burnett AL, Hatzichristou D, McCullough AR, Montorsi F, Mulhall JP. Phosphodiesterase type 5 inhibitors in postprostatectomy erectile dysfunction: A critical analysis of the basic science rationale and clinical application. Eur Urol 2009;55:334–47.
- 10 Schwartz EJ, Wong P, Graydon RJ. Sildenafil preserves intracorporeal smooth muscle after radical retropubic prostatectomy. J Urol 2004;171:771–4.
- 11 Iacono F, Prezioso D, Somma P, Chierchia S, Galasso R, Micheli P. Histopathologically proven prevention of postprostatectomy cavernosal fibrosis with sildenafil. Urol Int 2008;80:249–52.

- 12 Padma-Nathan H, McCullough AR, Levine LA, Lipshultz LI, Siegel R, Montorsi F, Giuliano F, Brock G. Study Group. Randomized, double-blind, placebo-controlled study of postoperative nightly sildenafil citrate for the prevention of erectile dysfunction after bilateral nerve-sparing radical prostatectomy. Int J Impot Res 2008;20:479–86.
- 13 Montorsi F, Brock G, Lee J, Shapiro J, Van Poppel H, Graefen M, Stief C. Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nervesparing radical prostatectomy. Eur Urol 2008;54:924–31.
- 14 Pavlovich CP, Levinson AW, Su LM, Mettee LZ, Feng Z, Bivalacqua TJ, Trock BJ. Nightly vs. on-demand sildenafil for penile rehabilitation after minimally invasive nerve-sparing radical prostatectomy: Results of a randomized double-blind trial with placebo. BJU Int 2013;112:844–51.
- 15 Montorsi F, Brock G, Stolzenburg JU, Mulhall J, Moncada I, Patel HR, Chevallier D, Krajka K, Henneges C, Dickson R, Büttner H. Effects of tadalafil treatment on erectile function recovery following bilateral nerve-sparing radical prostatectomy: A randomized placebo-controlled study (REACTT). Eur Urol 2014;65:587–96.
- 16 Leungwattanakij S, Bivalacqua TJ, Usta MF, Yang DY, Hyun JS, Champion HC, Abdel-Mageed AB, Hellstrom WJ. Cavernous neurotomy causes hypoxia and fibrosis in rat corpus cavernosum. J Androl 2003;24:239–45.
- 17 User HM, Hairston JH, Zelner DJ, McKenna KE, McVary KT. Penile weight and cell subtype specific changes in a postradical prostatectomy model of erectile dysfunction. J Urol 2003;169:1175–9.
- 18 Mullerad M, Donohue JF, Li PS, Scardino PT, Mulhall JP. Functional sequelae of cavernous nerve injury in the rat. Is there model dependency? J Sex Med 2006;3:77–83.
- 19 Iacono F, Giannella R, Somma P, Manno G, Fusco F, Mirone V. Histological alterations in cavernous tissue after radical prostatectomy. J Urol 2005;173:1673–6.
- 20 Angeloni NL, Bond CW, McVary KT, Podlasek CA. Sonic hedgehog protein is decreased and penile morphology is altered in prostatectomy and diabetic patients. PLoS ONE 2013;8:e70985.
- 21 Angulo J, González-Corrochano R, Cuevas P, Fernández A, La Fuente JM, Rolo F, Allona A, Sáenz de Tejada I. Diabetes exacerbates the functional deficiency of NO/cGMP pathway associated with erectile dysfunction in human corpus cavernosum and penile arteries. J Sex Med 2010;7:758–68.
- 22 Martínez-Salamanca JI, La Fuente JM, Cardoso J, Fernández A, Cuevas P, Wright HM, Angulo J. Nebivolol potentiates the efficacy of PDE5 inhibitors to relax corpus cavernosum and penile arteries from diabetic patients by enhancing the NO/cGMP pathway. J Sex Med 2014;11:1182–92.
- 23 González-Corrochano R, La Fuente JM, Cuevas P, Fernández A, Chen M, Sáenz de Tejada I, Angulo J. Ca²⁺-activated K⁺ channel (K_{Ca}) stimulation improves relaxant capacity of PDE5 inhibitors in human penile arteries and recovers the reduced efficacy of PDE5 inhibition in diabetes. Br J Pharmacol 2013;169:449–61.
- 24 Rambhatla A, Kovanecz I, Ferrini M, Gonzalez-Cadavid NF, Rajfer J. Rationale for phosphodiesterase 5 inhibitor use postradical prostatectomy: Experimental and clinical review. Int J Impot Res 2008;20:30–4.

- 25 Podlasek CA, González CM, Zelner DJ, Jiang HB, McKenna KE, McVary KT. Analysis of NOS isoform changes in a post radical prostatectomy model of erectile dysfunction. Int J Impot Res 2001;13(5 suppl):S1–15.
- 26 Jin HR, Chung YG, Kim WJ, Zhang LW, Piao S, Tuvshintur B, Yin GN, Shin SH, Tumurbaatar M, Han JY, Ryu JK, Suh JK. A mouse model of cavernous nerve injury-induced erectile dysfunction: Functional and morphological characterization of the corpus cavernosum. J Sex Med 2010;7:3351–64.
- 27 Yaman O, Yilmaz E, Bozlu M, Anafarta K. Alterations of intracorporeal structures in patients with erectile dysfunction. Urol Int 2003;71:87–90.
- 28 Cellek S, Moncada S. Nitrergic control of peripheral sympathetic responses in the human corpus cavernosum: A comparison with other species. Proc Natl Acad Sci USA 1997;94: 8226–31.
- 29 Mulhall JP, Müller A, Donohue JF, Mullerad M, Kobylarz K, Paduch DA, Tal R, Li PS, Cohen-Gould L, Scardino PT. The functional and structural consequences of cavernous nerve injury are ameliorated by sildenafil citrate. J Sex Med 2008;5:1126–36.
- 30 Albersen M, Fandel TM, Lin G, Wang G, Banie L, Lin CS, Lue TF. Injections of adipose tissue-derived stem cells and stem cell lysate improve recovery of erectile function in a rat model of cavernous nerve injury. J Sex Med 2010;7:3331– 40.
- 31 Nangle MR, Keast JR. Reduced efficacy of nitrergic neurotransmission exacerbates erectile dysfunction alter penile nerve injury despite axonal regeneration. Exp Neurol 2007; 207:30–41.
- 32 Palma CA, Keast JR. Structural effects and potential changes in growth factor signaling in penis-projecting autonomic neurons after axotomy. BMC Neurosci 2006;7:41.
- 33 Domes T, Chung E, DeYoung L, MacLean N, Al-Shaiji T, Brock G. Clinical outcomes of intracavernosal injection in postprostatectomy patients: A single-center experience. Urology 2012;79:150–5.
- 34 Fode M, Ohl DA, Ralph D, Sønksen J. Penile rehabilitation after radical prostatectomy: What the evidence really says. BJU Int 2013;112:998–1008.
- 35 Ferrini MG, Davila HH, Kovanecz I, Sanchez SP, Gonzalez-Cadavid NF, Rajfer J. Vardenafil prevents fibrosis and loss of corporal smooth muscle that occurs after bilateral cavernosal nerve resection in the rat. Urology 2006;68:429– 35.
- 36 Beetson K, Smith SF, Muneer A, Cameron NE, Cotter MA, Cellek S. Vasa nervorum in rat major pelvic ganglion are innervated by nitrergic nerve fibers. J Sex Med 2013;10:2967– 74.
- 37 Cellek S, Cameron NE, Cotter MA, Fry CH, Ilo D. Microvascular dysfunction and efficacy of PDE5 inhibitors in BPH-LUTS. Nat Rev Urol 2014;11:231–41.
- 38 Zhang RL, Chopp M, Roberts C, Wei M, Wang X, Liu X, Lu M, Zhang ZG. Sildenafil enhances neurogenesis and oligodendrogenesis in ischemic brain of middle-aged mouse. PLoS ONE 2012;7:e48141.
- 39 Santos AI, Carreira BP, Nobre RJ, Carvalho CM, Araújo IM. Stimulation of neural stem cell proliferation by inhibition of phosphodiesterase 5. Stem Cells Int 2014;2014:878397.

599